MAP1LC3A and neoplasm: Patients whose tumour had high expression of MAP1LC3A, SNCA, and MAPT and low expression of CDK1, AP1S1, CASP3, TMPRSS6, and GSK3B inferred better overall survival than all other patients (Fig. 4A).